Blockade of the inhibitory effects of galectin-1 within tumour tissue resulted in reduced tumour mass (an effect which required intact CD4+ and CD8+ T-cell responses) and stimulated the generation of a tumour-specific T-cell response in vivo. The gene discussed is CD4; the disease is neoplasm.